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Conclusions: This new tool would enable the risk-benefit 
judgements in addition to the rest of the TPS conventional 
parameters, for the optimal treatment choice. The big error 
bars shown in the pelvic cases, are due to the fact of 
considering the mean values of neutron doses obtained for a 
huge variety of treatments and techniques. They decrease 
when considering a more homogeneous inter-centres 
pathology, as the rectum. Treatments that combine low and 
high energies use a lower number of high energy MU and thus 
neutron doses are smaller. This fact should be considered in 
the script for future studies. A good concordance has been 
observed with previous studies [2] for these cases. Future 
works should be carried out to analyse other pathologies for a 
higher number of patients.  
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Purpose/Objective: Multicenter studies for pre-treatment 
planning verifications, sharing methodologies and acceptance 
criteria, could help in developing common procedures 
especially for SBRT treatments. The Italian Association of 
Medical Physics (AIFM) has created a working group dedicated 
to SBRT and one of the first group project was to perform 
pre-treatment quality assurance (QA) of common SBRT plans 
for prostate, liver and lung cancer among different Italian 
centers. 
Materials and Methods: Seventeen centres of the SBRT 
Italian working group verified, in pre-treatment mode, the 
SBRT plans according with their home technologies, 
methodologies and acceptance criteria. A questionnaire 
including personal Gamma criteria, if dose at isocenter was 
verified with ion chamber, Gamma Index results and if QA 
plans were considered deliverable or not. Data are presented 
as averages over the two patients for each anatomical 
district. 
Results: Sixty plans were analysed. The most common 
devices available on commerce were used (Gafchromic films, 
planar and cylindrical array of ion chamber or diode, EPID); 
the Gamma Analysis approach was local for 12 centres and 
global for 5 centres; in 75% of cases, DD and DTA criteria 
were 3%/3mm. For plans related to prostate region, the 
medium Gamma resulted 97.1% (range 92.1-99.7%); four 
centres verified dose at isocenter with a maximum deviation 
of 5.9%; all plans were considered clinically deliverable. For 
Liver region: 93.7% (range 84.9-98.0%); one centre verified 
dose at isocenter with a maximum deviation of 2.7%; two 
plans were considered not acceptable. For Lung region: 95.7% 
(range 86.1-99.0%); two centres verified dose at isocenter 
with a maximum deviation of 9.6%, one plan was considered 
not acceptable. 
 
 
 
 
Conclusions: This project showed differences in terms of the 
parameters considered with possible clinical implication. 
 
 
